ipragliflozin + mitiglinide calcium hydrate

This drug is a **fixed-dose combination of ipragliflozin and mitiglinide calcium hydrate**, formulated to treat type 2 diabetes mellitus. **Ipragliflozin** is a selective sodium-glucose co-transporter 2 (**SGLT2**) inhibitor: it reduces blood glucose levels by inhibiting renal glucose reabsorption in the proximal tubule, promoting urinary glucose excretion. **Mitiglinide calcium hydrate** is a rapid- and short-acting **insulin secretagogue** (a "glinide" class drug): it stimulates pancreatic insulin release by binding to the sulfonylurea receptor on pancreatic β-cells, thereby lowering postprandial blood glucose. The combination aims to address both fasting (via ipragliflozin) and postprandial glucose (via mitiglinide) elevations. Mechanistic synergy and pharmacokinetic interactions between the two drugs have been studied; both drugs have been developed and marketed in Japan and are known for their favorable safety profiles when used together[1][4].